Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ).
Shenzhen Hepalink Pharmaceutical Group has convened its 2025 annual general meeting for May 22, 2026 in Shenzhen, where shareholders will review the 2025 audited financial statements, decide on the profit distribution proposal, confirm directors’ remuneration, reappoint the external auditor and approve a change in the use of proceeds from its H-share issuance. The AGM will also vote on authorizing foreign-exchange derivative hedging, re-electing executive and independent non-executive directors, as well as approving the use of internal funds for wealth management products and cash management and setting a 2026 bank credit line and related guarantees, moves that collectively shape capital allocation, risk management and governance for the coming year.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a PRC-based pharmaceutical company listed in Hong Kong as an H-share issuer, focusing on the development, manufacturing and sale of heparin and related biologic and specialty pharmaceutical products for global markets. The group operates across both domestic and international healthcare sectors, reflecting its positioning as a cross-border life-sciences player.
Average Trading Volume: 633,254
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.62B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.